13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Cerebral Blood Flow and Metabolism
Cerebral blood flow (CBF) is the blood transfusion to the brain in a given period of time. In an adult, CBF is typically 750 millilitres per minute or 15% of the cardiac output. This compare to an average perfusion of 50 to 54 millilitres of blood per 100 grams of brain tissue per minute.An increase in hydrogen ion concentration lead to increased cerebral blood flow. A decrease in blood viscosity will increase cerebral blood flow. An increase in carbon dioxide levels results in increased cerebral blood flow.
Metabolism depends on a continuous circulatory supply of glucose and oxygen to neurons and astrocytes. In astrocytes, glucose is partly converted to lactate, which is then released in the extracellular space and taken up by neurons.With neuronal activity, lactate oxidation increases.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States